Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.

Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y, Aviel S, Galun E, Shaw HL, Eizenberg O, Hardan I, Shimoni A, Nagler A.

Clin Cancer Res. 2014 Jan 15;20(2):469-79. doi: 10.1158/1078-0432.CCR-13-1302. Epub 2013 Nov 18.

2.
3.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

4.

Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.

Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.

Transfusion. 2011 May;51(5):968-75. doi: 10.1111/j.1537-2995.2010.02896.x. Epub 2010 Sep 28.

PMID:
20880037
5.

[Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].

Pokrovskaia OS, Mendeleeva LP, Urnova ES, Gaponova TV, Gribanova EO, Alekseeva IV, Drokov MIu, Kalinin NN, Gretsov EM, Kliasova GA, Savchenko VG.

Ter Arkh. 2011;83(7):50-7. Russian.

PMID:
21894752
6.

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen D, Willemsen A, Whitaker N, Chabannon C.

Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.

8.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Stewart DA, Smith C, MacFarland R, Calandra G.

Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018.

10.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56. doi: 10.1016/j.bbmt.2008.11.028.

12.

Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.

Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A, Peled A.

Stem Cells. 2007 Sep;25(9):2158-66. Epub 2007 May 24.

13.

Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.

Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1128-35. doi: 10.1016/j.bbmt.2012.01.005. Epub 2012 Jan 14.

14.

The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.

Menéndez P, Caballero MD, Prosper F, Del Cañizo MC, Pérez-Simón JA, Mateos MV, Nieto MJ, Corral M, Romero M, García-Conde J, Montalbán MA, San Miguel JF, Orfao A.

Transfusion. 2002 Sep;42(9):1159-72.

PMID:
12430673
15.

Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone.

Kröger N, Zeller W, Hassan HT, Krüger W, Renges H, Hummel K, Gutensohn K, Lölliger C, Zander AR.

Ann Hematol. 1998 Jun;76(6):257-62.

PMID:
9692813
16.

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R, Díaz MA, Granda A, Bernardo MR, Escudero A, López-Lorenzo JL, Fernández-Rañada JM.

Bone Marrow Transplant. 1997 Aug;20(3):211-7.

17.

CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.

Hicks C, Isaacs A, Wong R, Chong BH.

Ann Hematol. 2011 May;90(5):547-55. doi: 10.1007/s00277-010-1097-8. Epub 2010 Oct 19.

PMID:
20957366
18.

Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.

Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C, Miller JS.

Exp Hematol. 2000 Jan;28(1):96-103. Erratum in: Exp Hematol. 2000 Mar;28(3):347.

PMID:
10658681
19.

Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.

Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.

Bone Marrow Transplant. 1997 Mar;19(6):529-37.

20.

[Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].

Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou SY, Zhou AP, Zhang CG, Ai B.

Ai Zheng. 2003 Dec;22(12):1311-6. Chinese.

PMID:
14693058

Supplemental Content

Support Center